Powder: -20°C for 3 years | In solvent: -80°C for 1 year
12(S)-HETrE is produced by 12-lipoxygenase oxidation of dihomo-γ-linolenic acid (DGLA). 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 μg | 35 days | $ 230.00 | |
50 μg | 35 days | $ 438.00 | |
100 μg | 35 days | $ 828.00 |
Description | 12(S)-HETrE is produced by 12-lipoxygenase oxidation of dihomo-γ-linolenic acid (DGLA). 12(S)-HETrE is reported to inhibit agonist-mediated platelet activation (IC50 = 40 μM), α granule secretion, integrin αIIbβ3 activation, Rap1 activation, and thrombin-induced clot retraction in vitro. |
Molecular Weight | 322.489 |
Formula | C20H34O3 |
CAS No. | 72710-10-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMF: Miscible
DMSO: Miscible
0.1 M Na2CO3: 2 mg/mL
PBS (pH 7.2): 0.8 mg/mL
Ethanol: Miscible
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
12(S)-HETrE 72710-10-2 12HETrE 12(S)HETrE 12(S) HETrE inhibitor inhibit